Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

- 1 min read

Japan's Olympus names Stefan Kaufmann as next CEO in medtech pivot

Tokyo, October 21. 2022 (Reuters) -- Olympus Corp (7733.T) said on Friday that Stefan Kaufmann would become the endoscope maker's chief executive next year, becoming one of the few foreigners to run a major Japanese company.

Read full article here.

Recent Posts

See All

Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer

Oxford, UK, November 22, 2022 (Yahoo) -- Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces the appointment of Dr Frank Math

Bonum Therapeutics Announces a $93M Series A Financing for Conditionally Active Therapies

Seattle, WA, November 15, 2022 (Business Wire) -- Bonum Therapeutics, a biopharmaceutical company using allosteric regulation to create conditionally active and less toxic medicines, today announced

Invacare Appoints Geoff Purtill President and Chief Executive Officer

Elyria, OH, November 21, 2022 (Business Wire) -- Invacare Corporation (NYSE: IVC) announced today that its Board of Directors has named Geoffrey P. Purtill as President and Chief Executive Officer,

Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer

Bonum Therapeutics Announces a $93M Series A Financing for Conditionally Active Therapies

Invacare Appoints Geoff Purtill President and Chief Executive Officer

FogPharma Announces $178 Million Series D Financing to Advance Helicon Polypeptide Therapeutics

Teva Announces Appointment of Richard Francis as President and CEO

Align Technology Announces $200 Million Accelerated Stock Repurchase Agreement Under Its $1 Billion

Michael Aldridge, Seasoned Biotech Executive, Appointed CEO of Focal Medical

Emalex Biosciences Announces $250 Million Financing to Advance New Drug for Tourette Syndrome

Normunity Announces $65 Million Series a Financing to Expand Frontier of Precision Immuno-Oncology

AbbVie Announces Acquisition of DJS Antibodies for $255m

Executive Spotlights

Japan's Olympus names Stefan Kaufmann as next CEO in medtech pivot

Recent Posts

Life Science Headlines